Fagron NV (EBR:FAGR)

Market Cap	1.40B
Revenue (ttm)	874.84M
Net Income (ttm)	80.55M
Shares Out	72.99M
EPS (ttm)	1.10
PE Ratio	17.49
Forward PE	14.15
Dividend	0.30 (1.55%)
Ex-Dividend Date	May 21, 2024

Volume	142,439
Average Volume	71,402
Open	19.42
Previous Close	19.38
Day's Range	19.12 - 19.54
52-Week Range	15.14 - 20.15
Beta	0.32
RSI	53.83
Earnings Date	Feb 20, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan use...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,282
• Stock Exchange: Euronext Brussels
• Ticker Symbol: FAGR

Financial Performance

In 2024, Fagron NV's revenue was 874.84 million, an increase of 14.66% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.